HC Wainwright & Co. Upgrades Collegium Pharmaceutical to Buy, Announces $47 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has upgraded Collegium Pharmaceutical (NASDAQ:COLL) from Neutral to Buy, with a new price target of $47.
July 30, 2024 | 11:54 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has upgraded Collegium Pharmaceutical from Neutral to Buy, setting a new price target of $47. This upgrade could positively impact the stock price in the short term.
The upgrade from Neutral to Buy by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence and drive the stock price higher in the short term. The new price target of $47 suggests significant upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100